You are here

ACH-3102

J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market

Endpoints

Mon, 09/11/17 - 09:40 am

3 Small-Cap Biotech Stocks With Big News Coming in 2016

Motley Fool

Sat, 12/12/15 - 02:05 pm

Portola Pharmaceuticals

Johnson & Johnson And Achillion Pharmaceuticals May Offer Fastest 100% Cure With Their HCV Combo

Bidness, ETC

Fri, 09/18/15 - 10:56 am

Gilead Sciences

5 Drugs That Investors May Be Undervaluing

Motley Fool

Mon, 07/13/15 - 11:04 am

Amicus Therapeutics

Gilead Sciences

Achillion HCV-1 regimen achieves 100% SVR12 at six weeks

Seeking Alpha

Mon, 02/9/15 - 08:26 am

Gilead Sciences

Achillion Pharma rises on results from study combining hepatitis C drugs ACH-3102 and Sovaldi

Yahoo/AP

Mon, 11/10/14 - 03:55 pm

Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)

Yahoo/Globe NewsWire

Sat, 11/8/14 - 10:39 am

Biotech Stock Achillion Is Soaring After Good News About Its Hepatitis C Drug

Yahoo/Business Insider

Fri, 08/15/14 - 11:30 am

Achillion May Be The Most Underrated Biotech Left

Seeking Alpha

Wed, 06/26/13 - 09:35 am

Bristol-Myers Squibb

Vertex Pharmaceuticals

Achillion Says Hepatitis C Drug Subdues Virus in 63% of Patients

Bloomberg

Tue, 04/23/13 - 07:57 am

5 Drug Hopefuls That Are Going to Change Your Life: Part 2

Motley Fool

Sat, 11/24/12 - 12:01 pm

Gilead Sciences

Bristol-Myers Squibb

Abbott Laboratories

Achillion Announces Positive Proof-of-Concept Data With ACH-3102

Yahoo

Thu, 09/27/12 - 10:51 am

Achillion's hepatitis C drug gets FDA fast track

Reuters

Tue, 05/15/12 - 12:11 pm

5 Biotech Stocks That Could Soar On New Hepatitis C Drugs

Seeking Alpha

Sat, 04/21/12 - 12:17 pm

Abbott Laboratories

Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C

Yahoo/Globe NewsWire

Sat, 04/21/12 - 12:05 pm